Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137 is registered in ClinicalTrials.gov with Ebrahim Delpassand as lead sponsor.

NCT NCT02282137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02282137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Lead sponsor
Ebrahim Delpassand
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2023
Enrollment
208 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer